Oren Gilad - 10 Oct 2024 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
President/CEO, Director
Signature
/s/ John Hamill, as Attorney-in-Fact
Issuer symbol
APRE
Transactions as of
10 Oct 2024
Net transactions value
+$2,971
Form type
4
Filing time
15 Oct 2024, 08:31:01 UTC
Previous filing
28 Mar 2024
Next filing
16 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Purchase $381 +150 +0.05% $2.54 331,645 10 Oct 2024 Direct
transaction APRE Common Stock Purchase $2,590 +1,000 +0.3% $2.59 332,645 14 Oct 2024 Direct
holding APRE Common Stock 1,200 10 Oct 2024 By Daughter F1
holding APRE Common Stock 600 10 Oct 2024 By Son F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.